Skip to Main content Skip to Navigation
Journal articles

Calcite as a bone substitute. Comparison with hydroxyapatite and tricalcium phosphate with regard to the osteoblastic activity

Abstract : Close to the bone mineral phase, the calcic bioceramics, such as hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP), are commonly used as substitutes or filling materials in bone surgery. Besides, calcium carbonate (CaCO3) is also used for their excellent biocompatibility and bioactivity. However, the problem with the animal-origin aragonite demands the new technique to synthesize pure calcite capable of forming 3D bone implant. This study aims to manufacture and evaluate a highly-pure synthetic crystalline calcite with good cytocompatibility regarding to the osteoblasts, comparing to that of HA and β-TCP. After the manufacture of macroporous bioceramic scaffolds with the identical internal architecture, their cytocompatibility is studied through MC3T3-E1 osteoblasts with the tests of cell viability, proliferation, vitality, etc. The results confirmed that the studied process is able to form a macroporous material with a controlled internal architecture, and this synthesized calcite is non-cytotoxic and facilitate the cell proliferation. Indeed requiring further improvement, the studied calcite is definitely an interesting alternative not only to coralline aragonite but also to calcium phosphate ceramics, particularly in bone sites with the large bone remodelling.
Complete list of metadatas

https://hal-uphf.archives-ouvertes.fr/hal-03032812
Contributor : Julie Cagniard <>
Submitted on : Tuesday, December 1, 2020 - 9:36:30 AM
Last modification on : Wednesday, December 2, 2020 - 3:23:36 AM

Identifiers

Citation

F. Monchau, Ph. Hivart, B. Genestie, F. Chai, Michel Descamps, et al.. Calcite as a bone substitute. Comparison with hydroxyapatite and tricalcium phosphate with regard to the osteoblastic activity. Materials Science and Engineering: C, Elsevier, 2013, 33 (1), pp.490-498. ⟨10.1016/j.msec.2012.09.019⟩. ⟨hal-03032812⟩

Share

Metrics

Record views

22